- Home
- STTK vs TLRY Comparison
STTK vs TLRY Comparison
Compare STTK & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | TLRY |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.8M | 570.4M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STTK | TLRY |
|---|---|---|
| Price | $7.30 | $4.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.00 | ★ $72.33 |
| AVG Volume (30 Days) | 1.3M | ★ 4.7M |
| Earning Date | 05-01-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 55.69 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | N/A | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.77 |
| 52 Week High | $8.33 | $15.70 |
Technical Indicators
Market Signals| Indicator | STTK | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 57.54 |
| Support Level | $5.87 | $4.20 |
| Resistance Level | $7.75 | $4.90 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 55.08 | 81.60 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.